Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, is pleased to announce that all resolutions have been duly passed by shareholders at the Annual General Meeting held today.
The full text of each resolution is set out in the Notice of Annual General Meeting, included in the 2022 Annual Report, which is available under the Investor Resources section of the Company’s website https://avacta.com/investors/investor-resources/.
All presentation materials provided to shareholders, including slide decks and posters, can also be found here.